                         SEQUENCE LISTING

<110>  Manucharyan, Karen
       Primex Clinical Laboratories
        
<120>  Identification and Generation of personalized vaccine components 
       by functional screening assay using variable epitope and mimotope
        libraries and peripheral blood mononuclear cells

<130>  4727/1011WO

<150>  US 62/395,067
<141>  2016-09-15

<160>  38    
<170>  PatentIn version 3.5

<210>  1
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence derived from a survivin CTL epitope


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  Xaa can be any naturally occurring amino acid

<400>  1

Gly Trp Xaa Pro Xaa Asp Xaa Pro Ile 
1               5                   


<210>  2
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino acid sequence derived from a survivin CTL epitope

<400>  2

Gly Trp Glu Pro Asp Asp Asn Pro Ile 
1               5                   


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Amino Acid Sequence derived from a Mimotope


<220>
<221>  MISC_FEATURE
<222>  (4)..(4)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  MISC_FEATURE
<222>  (8)..(8)
<223>  Xaa can be any naturally occurring amino acid

<400>  3

Ala Gly Pro Xaa Ala Xaa Ala Xaa Leu 
1               5                   


<210>  4
<211>  57
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleic acid primer sequence corresponding to a survivin CTL  
       epitope

<400>  4
gtatattact gtgcgggttg ggaaccagat gataatccaa tatggggcca gggaacc          57


<210>  5
<211>  57
<212>  DNA
<213>  Artificial Sequence

<220>
<223>   Nucleic acid primer sequence corresponding to a survivin CTL 
       epitope


<220>
<221>  misc_feature
<222>  (22)..(23)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (24)..(24)
<223>  k is c or g

<220>
<221>  misc_feature
<222>  (28)..(29)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (30)..(30)
<223>  k is c or g

<220>
<221>  misc_feature
<222>  (34)..(35)
<223>  n is a, c, g, or t

<220>
<221>  misc_feature
<222>  (36)..(36)
<223>  k is c or g

<400>  5
gtatattact gtgcgggttg gnnkccannk gatnnkccaa tatggggcca gggaacc          57


<210>  6
<211>  39
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleic acid primer sequence corresponding to a survivin CTL  
       epitope

<400>  6
tgatattcgt actcgagcca tggtgtatat tactgtgcg                              39


<210>  7
<211>  40
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleic acid primer sequence corresponding to a survivin CTL  
       epitope

<400>  7
atgattgaca aagcttggat ccctaggttc cctggcccca                             40


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  8

Gly Trp Phe Pro Leu Asp Ala Pro Ile 
1               5                   


<210>  9
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  9

Gly Trp Leu Pro Asn Asp Tyr Pro Ile 
1               5                   


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  10

Gly Trp Arg Pro Thr Asp Val Pro Ile 
1               5                   


<210>  11
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  11

Gly Trp Phe Pro Leu Asp Asn Pro Ile 
1               5                   


<210>  12
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  12

Gly Trp Ile Pro Ser Asp Phe Pro Ile 
1               5                   


<210>  13
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  13

Gly Trp Gln Pro Thr Asp Glu Pro Ile 
1               5                   


<210>  14
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  14

Gly Trp Thr Pro Lys Asp Asp Pro Ile 
1               5                   


<210>  15
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  15

Gly Trp Asp Pro Leu Asp Ile Pro Ile 
1               5                   


<210>  16
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  16

Gly Trp Gln Pro Met Asp Ser Pro Ile 
1               5                   


<210>  17
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  17

Gly Trp Ile Pro Thr Asp Ala Pro Ile 
1               5                   


<210>  18
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  18

Gly Trp Cys Pro Tyr Asp Thr Pro Ile 
1               5                   


<210>  19
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  19

Gly Trp Asn Pro Ser Asp Leu Pro Ile 
1               5                   


<210>  20
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  20

Gly Trp Val Pro Thr Asp Leu Pro Ile 
1               5                   


<210>  21
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  21

Gly Trp His Pro Leu Asp Asn Pro Ile 
1               5                   


<210>  22
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  22

Gly Trp Asn Pro Phe Asp Gly Pro Ile 
1               5                   


<210>  23
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  23

Gly Trp Asp Pro Leu Asp Gln Pro Ile 
1               5                   


<210>  24
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  24

Gly Trp Ala Pro Asn Asp Asn Pro Ile 
1               5                   


<210>  25
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  25

Gly Trp Val Pro Asp Asp Tyr Pro Ile 
1               5                   


<210>  26
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  26

Gly Trp Gln Pro Val Asp Arg Pro Ile 
1               5                   


<210>  27
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  27

Gly Trp Glu Pro Thr Asp His Pro Ile 
1               5                   


<210>  28
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  28

Gly Trp Cys Pro Gln Asp Leu Pro Ile 
1               5                   


<210>  29
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  29

Gly Trp Trp Pro Gln Asp Glu Pro Ile 
1               5                   


<210>  30
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  30

Gly Trp Phe Pro Leu Asp Val Pro Ile 
1               5                   


<210>  31
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  31

Gly Trp Val Pro Tyr Asp Tyr Pro Ile 
1               5                   


<210>  32
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  32

Gly Trp Arg Pro Val Asp Pro Pro Ile 
1               5                   


<210>  33
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Variant of wild-type survivin epitope

<400>  33

Gly Trp Thr Pro Ile Asp Arg Pro Ile 
1               5                   


<210>  34
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Mimotope Variant


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  x is Glycine or Phenylalainine of

<220>
<221>  MISC_FEATURE
<222>  (4)..(8)
<223>  x is anyaminio acid

<220>
<221>  MISC_FEATURE
<222>  (9)..(9)
<223>  x is leucine or methionine

<400>  34

Ala Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa 
1               5                   


<210>  35
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mimotope variant

<400>  35

Ala Gly Pro Ala Ala Ala Ala Ala Leu 
1               5                   


<210>  36
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Her2 derived epitope

<400>  36

Thr Tyr Leu Pro Thr Asn Ala Ser Leu 
1               5                   


<210>  37
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  mouse Her2-derived epitope

<400>  37

Thr Tyr Leu Pro Ala Asn Ala Ser Leu 
1               5                   


<210>  38
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Her2 epiotpe variant


<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  where x is any natural amino acid

<220>
<221>  MISC_FEATURE
<222>  (5)..(5)
<223>  where x is any natural amino acid

<220>
<221>  MISC_FEATURE
<222>  (7)..(7)
<223>  where x is any natural amino acid

<400>  38

Thr Tyr Xaa Pro Xaa Asn Xaa Ser Leu 
1               5                   


